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Abstract
The broadly-neutralizing anti-HIV antibody 4E10 recognizes an epitope in the membrane-proximal external region of the
HIV envelope protein gp41. Previous attempts to elicit 4E10 by vaccination with envelope-derived or reverse-engineered
immunogens have failed. It was presumed that the ontogeny of 4E10-equivalent responses was blocked by inherent
autoreactivity and exceptional polyreactivity. We generated 4E10 heavy-chain knock-in mice, which displayed significant B
cell dysregulation, consistent with recognition of autoantigen/s by 4E10 and the presumption that tolerance mechanisms
may hinder the elicitation of 4E10 or 4E10-equivalent responses. Previously proposed candidate 4E10 autoantigens include
the mitochondrial lipid cardiolipin and a nuclear splicing factor, 3B3. However, using carefully-controlled assays, 4E10 bound
only weakly to cardiolipin-containing liposomes, but also bound negatively-charged, non-cardiolipin-containing liposomes
comparably poorly. 4E10/liposome binding was predominantly mediated by electrostatic interactions rather than presumed
hydrophobic interactions. The crystal structure of 4E10 free of bound ligands showed a dramatic restructuring of the
combining site, occluding the HIV epitope binding site and revealing profound flexibility, but creating an electropositive
pocket consistent with non-specific binding of phospholipid headgroups. These results strongly suggested that antigens
other than cardiolipin mediate 4E10 autoreactivity. Using a synthetic peptide library spanning the human proteome, we
determined that 4E10 displays limited and focused, but unexceptional, polyspecificity. We also identified a novel
autoepitope shared by three ER-resident inositol trisphosphate receptors, validated through binding studies and
immunohistochemistry. Tissue staining with 4E10 demonstrated reactivity consistent with the type 1 inositol trisphosphate
receptor as the most likely candidate autoantigen, but is inconsistent with splicing factor 3B3. These results demonstrate
that 4E10 recognition of liposomes competes with MPER recognition and that HIV antigen and autoepitope recognition
may be distinct enough to permit eliciting 4E10-like antibodies, evading autoimmunity through directed engineering.
However, 4E10 combining site flexibility, exceptional for a highly-matured antibody, may preclude eliciting 4E10 by
conventional immunization strategies.
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Introduction
An effective prophylactic AIDS vaccine will need to generate
anti-HIV neutralizing antibodies (Abs) that target the HIV
envelope glycoprotein (Env) [1–3] and broadly neutralize as many
HIV isolates as possible (bNAbs). The bNAb 4E10 [4–10]
recognizes an epitope that is highly conserved across HIV-1,
HIV-2, and SIV and displays one of the widest breadths of any
anti-HIV bNAb, neutralizing 98% of HIV-1 strains [11,12]. These
properties have made 4E10 an attractive vaccine target, but
previous attempts to elicit 4E10 or equivalent Abs through
vaccination have failed.
The HIV envelope protein (Env) consists of gp120 surface
subunits and gp41 membrane-anchoring subunits assembled as
noncovalent trimers of gp120/gp41 heterodimers to form mature,
functional ‘spikes’ on the virion surface. 4E10 recognizes a
conserved linear epitope (consensus clade B sequence:
671NWFDITNWLW680; core epitope: NWFD/NIT), immediately
adjacent to the viral membrane in the gp41 membrane proximal
external region (MPER) [4,10]. bNAbs targeting the MPER, such
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as 4E10 and a second bNAb, 2F5, are uncommon in infected
individuals, and Env-derived immunogens do not efficiently elicit
these Abs in vaccinees [13,14]. 2F5 recognizes a linear epitope
(consensus clade B sequence: 662ELDKWA667) neighboring the
4E10 epitope in the MPER [15]. It has been proposed that these
Abs are inherently polyspecific and autoreactive as a direct
consequence of their epitope specificity and neutralization
mechanism, which has been posited to require interactions with
lipids and viral membrane components in addition to and outside
of their peptide epitopes [16–20]. Therefore, B cell tolerance
mechanisms would limit the natural production of MPER-specific
bNAbs, like 2F5 and 4E10, in people infected with HIV and
hinder the elicitation of equivalent bNAbs by vaccination.
Structural elements of 4E10 that have been proposed to mediate
lipid or liposome recognition include the long, hydrophobic heavy
chain complementarity determining region 3 (HCDR3) sequence
and, in particular, the side-chain of residue W100H, which
protrudes from the tip of HCDR3 at a position predicted to
penetrate the viral membrane when bound to Env, based on the
4E10/epitope peptide complex crystal structure [10] and muta-
genesis studies [21,22].
Polyspecificity is the property of recognizing multiple distinct
ligands (recognition degeneracy) combined with the specificity
with which each of those ligands is recognized [23,24]. Poly-
specificity is particularly important for the function of adaptive
immunoreceptors (T cell receptors and B cell receptors (BCRs)),
which are functionally enhanced by broadly recognizing foreign
antigens. Autoreactivity is the potential downside of unchecked
polyspecificity, although autoreactivity does play a role in B cell
activation and regulation (reviewed in [25–27]). On the order of
50% of newly-rearranged BCRs are estimated to be autoreactive
and some degree of self-reactivity is necessary to pass through
positive selection during B cell development; self-recognition by
the pre-BCR induces the expansion of precursor cells and
broadens antibody diversity. Autoreactivity can be defined
functionally as dysregulation of B cell development (e. g. the
developmental arrest, loss of immature B cells to central tolerance
mechanisms and reduced numbers of residual splenic B cells with
low surface IgM density observed in homozygous 2F5 VHDJH
knock-in mice [28]) or in vitro with binding assays or immunoflu-
orescence (IF) staining [29].
In vivo experiments demonstrating functional 4E10 autoreactiv-
ity had not been reported when we started these studies. 2F5 and
4E10 were originally concluded to be polyspecific and autoreactive
on the basis of binding assays against 11 purified lipidic and
nuclear autoantigens [16,19]. 2F5 and 4E10 also both showed
HEp-2 cell reactivity, exhibiting diffuse cytoplasmic and weaker
nuclear staining patterns [19]. On the basis of these results, the
4E10 autoantigen was proposed to be the mitochondrial dipho-
sphatidylglycerol lipid cardiolipin (CL) [30,31], though 4E10 also
showed comparable cross-reactivity against every lipid tested,
including phosphatidylserine (PS), phosphatidylcholine (PC),
phosphatidylethanolamine (PE) and sphingomyelin (SM). Howev-
er, detection of clinically-relevant anti-CL autoantibodies (ACLA)
by simple binding assays with isolated antigens, as has been
previously reported [16], is associated with high false positive rates,
representing challenges in the laboratory characterization of sera
and Abs and the clinical evaluation of autoantibody induced
morbidity [32]. More quantitative assays have been contradictory,
with an estimated equilibrium dissociation constant (KD) in the low
micromolar range in one study [18] but weaker, unquantifiable
binding in others [33,34]; 4E10 was reported to bind to model
viral liposomes which did not contain CL with a sub-micromolar
KD [21], but showed no binding to ‘bald’, proteolytically-digested
virus-like particles [35]. The disagreement of these results is due, in
part, to employed methodologies, such as surface plasmon
resonance (SPR), that can be difficult to reproduce and hard to
evaluate in the absence of positive controls and when analyzing
interactions with lipidic species [36].
Abs against phospholipids, including ACLA, are seen in
primary antiphospholipid syndrome (APS) or in association with
other autoimmune diseases, such systemic lupus erythematosus
(SLE). ACLA in this context generally do not recognize CL in
isolation, but as complexes with the phospholipid-binding serum
protein b2 glycoprotein I (b2GPI) or other proteins with anti-
coagulant activity. The presence of ACLA in these conditions can
provoke serious complications, including arterial and venous
thromboses and recurrent miscarriages. A second class of
antiphospholipid antibodies can be generated after certain viral
and bacterial infections, such as HIV, hepatitis B and C, syphilis
and leprosy. ACLA are found in approximately 50% of people
infected with HIV (versus ,2% of uninfected controls) and are
strongly linked with the level of viral replication, the level of B cell
activation and the level of MPER-specific Abs [37,38]; however,
these Abs are usually not associated with APS manifestations and
are not dependent on b2GPI for binding [39]. If 4E10 CL
autoreactivity is sufficiently strong to trigger B cell tolerance
mechanisms, it might be expected that 4E10 would contribute to
APS; however, 4E10 showed only weak activity in APS clinical
assays [33] and passive infusion studies [40], similar to that of
antiphospholipid antibodies elicited during infections rather than
that of ACLA.
While polyreactive across phospholipids, subsequent experi-
ments with larger antigen arrays (a microarray of 106 connective
tissue disease-related autoantigens plus controls [41] or the
UNIchip AV-400 panel of 400 bacterially-expressed human
proteins [33]) concluded that anti-HIV bNAbs were either not
exceptionally polyreactive, including 2F5, 4E10 and the anti-CD4
binding site antibody b12, or displayed only limited polyreactivity,
including 2F5 and 4E10 [42,43]. The reactivity profile of 4E10
was, therefore, concluded to be fundamentally distinct from those
Author Summary
4E10 is an example of an anti-HIV, broadly neutralizing
antibody that is uncommon in infected patients and has
not been successfully elicited by any vaccine approach
attempted. 4E10 has been proposed to neutralize HIV
through a mechanism that requires broad recognition of
other antigens, including membrane phospholipids. Such
a mechanism would also block the generation of 4E10
during B cell development, confounding vaccination
strategies. Analysis of B cell development in 4E10 heavy-
chain knock-in mice confirmed that 4E10 does recognize
self-antigens. However, a previously proposed autoantigen
candidate, the mitochondrial lipid cardiolipin, was not
consistent with binding studies which showed that while
4E10 does bind liposomes containing cardiolipin, it does
so only weakly and nonspecifically, also binding liposomes
without cardiolipin. Using a synthetic human peptidome,
4E10 was shown to be polyreactive, binding peptides from
various proteins, but only in a limited manner. Three of the
top five hits are from types 1, 2 and 3 inositol trispho-
sphate receptors, with high scoring peptides sharing a
conserved sequence motif. Validation of the top hits was
performed by binding analyses and staining of tissue
sections, which combined to identify the type 1 inositol
trisphosphate receptor as the most likely 4E10 physiolog-
ical autoantigen.
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of pathogenic autoantibodies that would trigger B cell tolerance
mechanisms [41]. However, a recent analysis of 4E10 binding to a
commercially-available array (Invitrogen ProtoArray 5) of 9,000
intact human proteins, expressed in baculovirus as GST-fusion
proteins, concluded that 4E10 displayed ‘‘exceptional polyreactiv-
ity’’ on the basis of very broad, but low-avidity binding [20].
In this report, we found that knocking-in the 4E10 heavy chain
into murine B cells results in comparable levels of dysregulation in
the B cell compartment as had been observed in 2F5 heavy chain
knock-in mice, demonstrating significant inherent autoreactivity,
which was confirmed by clear patterns of specific autoreactivity by
immunohistochemistry (IHC) on murine tissue sections. We
determined that 4E10 does not stain mitochondria in HEp-2 cells
in vitro or in tissue sections and that 4E10 bound only relatively
weakly, but comparably, to liposomes containing CL or virus-like
compositions lacking CL in well-controlled SPR binding assays
using improved methodologies [36]. Therefore, 4E10 phospho-
lipid binding is relatively weak, not specific for CL compared to
other phospholipids, and distinct from properties of true ACLA
responses. In order to isolate the 4E10 structural elements that
might mediate general phospholipid binding activity, binding
studies were performed with engineered HCDR3-grafted ubiqui-
tin (Ubq) fusion constructs, with 4E10 point mutants, and at
varying ionic strengths, which showed that the weak phospholipid
binding activity displayed by 4E10 is driven by electrostatic
interactions, not hydrophobic ones. The overall positive charge of
the 4E10 Fv cassette, a property of many anti-HIV bNAbs [44],
does not account for this behavior, which is likely alternately
driven by an electropositive pocket present in the dramatically
restructured combining site of ligand-free 4E10 but absent in
epitope bound-state structures. However, 4E10, in either confor-
mational state (free or complexed), lacks structural features
required for truly specific recognition of CL. We therefore
conclude that CL is unlikely to be the physiologically-relevant
self-antigen mediating 4E10 autoreactivity and deletion during B
cell development.
Because 4E10 was clearly autoreactive in 4E10 knock-in mice,
we sought to identify candidates for bona fide 4E10 autoantigens
using a synthetic library of 413,611 36-mer peptides spanning the
human proteome combined with phage immunoprecipitation
sequencing (PhIP-Seq) [45]. The results identify a short list of
protein candidates, validated by in vitro binding studies and
consistent with IHC results. The PhIP-Seq results were also useful
for more finely defining 4E10 polyspecificity beyond previous
studies, leading to the conclusion that 4E10 displays limited, highly
focused polyspecificity, unexceptional for this class of molecules.
Our findings should inform future attempts to generate 4E10-
equivalent functionalities by vaccination and determine the precise
molecular mechanism of 4E10 neutralization of HIV.
Results
Impaired B cell development and function in 4E10 heavy
chain (4E10H) knock-in mice
In order to evaluate the potential self-reactivity of 4E10, the
rearranged human IgH VDJ antigen-binding domain of the 4E10
gene was targeted to the mouse immunoglobulin heavy chain
(IgH) locus in B6 embryonic stem cells. B cell development in the
derived 4E10H+/+ knock-in mice was evaluated by flow cytometry
and compared with both wild-type B6 and control KL25H+/+
knock-in mice (Fig. 1A). KL25H+/+ knock-in mice express from
the mouse IgH locus the rearranged mouse IgH VDJ antigen-
binding domain of the LCMV-neutralizing antibody [46]. Flow
cytometric analysis of bone marrow-resident B220+ cells from
4E10H+/+ knock-in mice revealed a dramatic reduction of both
B220+IgM+IgD2 pre-B cells and B220+IgM+IgD+ immature B
cells when compared with B6 mice. In contrast, KL25H knock-in
mice displayed normal populations of developing B cells. These
results suggest that expression of the 4E10 Ig heavy chain led to
deletion of the majority of developing B cells as a result of self-
antigen recognition.
Although there was a profound defect in B cell development,
low numbers of B220+ B cells could still be found in the spleens
and lymph nodes of 4E10H knock-in mice, suggesting that some
4E10H-expressing B cells had escaped deletion during develop-
ment. To determine whether putative autoreactivity had impaired
the function of 4E10H-expressing B cells, we tested the ability of
these cells to respond to mitogenic and antigen receptor stimuli in
vitro. Splenocytes were purified from 4E10H+/+, KL25H+/+, and
WT B6 mice, loaded with cell proliferation dye eFlour670, and
cultured overnight in the presence of LPS, CpG DNA, an
activating anti-CD40 antibody, anti-IgM F(ab9)2, or in culture
media alone (no stimulus). The following day, B cell proliferation
was assessed by flow cytometric measurement of dye dilution in
B220+ cells (Fig. 1B). B220+ B cells from 4E10H, KL25H, and
WT mice placed in culture media alone remained highly stained
with proliferation dye, indicating they had not undergone cell
division. 4E10H+/+, KL25H+/+, and WT B6 B cells diluted the
dye after treatment with LPS, CpG DNA, or anti-CD40,
indicating that these cells had undergone cell division. This
suggested that 4E10H-expressing B cells were capable of
responding to a variety of mitogenic signals and did not have a
general cellular activation defect. However, while both KL25H+/+
and B6 B cells proliferated in response to IgM cross-linking,
4E10H+/+ B cells did not, suggesting that these cells were anergic
to antigen receptor signaling, a phenotype consistent with self-
antigen reactivity.
4E10 bound liposomes only weakly, but predominately
through electrostatic interactions
Having confirmed that 4E10H was autoreactive in a murine
background, we sought to characterize 4E10 interactions with CL
in order to determine definitively whether the affinity and
specificity for this phospholipid biochemically met criteria for
autorecognition. We tested binding of 4E10 IgG to liposomes
captured on SPR biosensors with three different compositions
approximating (i) the external leaflet of cellular membranes (PC/
cholesterol), (ii) membranes containing CL (PC/cholesterol/CL)
or (iii) the HIV viral envelope (PC/SM/PE/PS/cholesterol [22]).
We also incorporated improvements into these SPR protocols
compared to previous analyses. Liposomes were prepared with
biotinylated lipids (0.5% w/w) and captured on streptavidin-
coated sensor chips (Biacore SA chips (GE)) [47] rather than
adsorbing prepared liposomes to lipophilic groups covalently
attached to carboxymethylated dextran-coated sensor chips
(Biacore L1 chips (GE)). This approach reduces the need to block
dextran lipid groups with either saturating amounts of liposomes
or directly chip-coupled bovine serum albumin (BSA), improving
signal-to-noise ratios, and has been determined to generate much
more consistent and reliable results than L1 sensor chips [36] or
ELISA-based methods [32,48]. BSA was added to all analyte
buffers throughout analysis to act as a blocking reagent, preventing
nonspecific binding. Annexin V, which binds to both CL and PS
[37], was used as a positive control in order to provide
comparative responses. Double subtraction [49] was also used to
correct sensorgrams, which were run in duplicate, where both
reference cell and buffer-matched blank responses are considered.
Autoreactivity and Polyspecificity of bNAb 4E10
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These combined improvements result in SPR sensorgrams that
show cleanly negative results for the binding of Abs and Annexin
V to control liposomes (PC/cholesterol) but clear, reproducible,
positive results for Annexin V binding to liposomes incorporating
CL or PS (Fig. 2). 2F5 and b12 monoclonal IgGs and a patient-
derived ACLA polyclonal antiserum did not bind appreciably to
liposomes of any composition tested. However, 4E10 IgG showed
weak, but reproducible binding to CL liposomes containing PC,
cholesterol and CL and virus-like liposomes containing PE, PC,
PS, SM and cholesterol, but lacking CL. However, while
detectable, the SPR binding responses, which reflect bivalent
avidities, could not be quantified accurately, due to the weak
responses and distinct, biphasic association profiles unfittable by
any reasonable model. Nevertheless, 4E10 binding responses to
CL and virus-like liposomes were qualitatively comparable,
demonstrating a lack of specificity for CL over other negatively-
charged phospholipids. 4E10 IgG, the bivalent form, was used in
these experiments because univalent reagents, like scFvs [34], did
not display detectable binding (data not shown), confirming the
weakness of these interactions in absolute terms.
It had been hypothesized that the HCDR3 of 4E10 makes
direct hydrophobic contacts with the viral membrane, facilitating
binding through aromatic and apolar amino acid side-chains,
particularly W100H and W100bH [21]. In order to test whether
or not 4E10 HCDR3 alone supports liposome binding, HCDR3-
grafted Ubq fusions were designed (Fig. 3A). Ubq is a small, stable
protein with an exposed loop (residues 46–47) bracketed by
residues spaced by the same distance as the framework residues
bracketing HCDR3 in Abs. The fusions were generated by
replacing this two residue loop in Ubq with the HCDR3 sequences
of 2F5, b12 or 4E10. The three Ubq fusion constructs, expressed
in bacteria, were monodisperse in solution after purification,
determined by size-exclusion chromatography (SEC; Fig. 3B),
and showed detectable, but weak binding to chip-coupled HIV
SF162 gp140 by SPR (Fig. 3C), confirming their utility for
biochemical assays. However, all three HCDR3-grafted Ubq
fusions failed to show any binding response by SPR to liposomes of
any composition tested (Fig. 3D), even at relatively high analyte
concentrations, showing that hydrophobic HCDR3 sequences
alone, out of context of the rest of the folded Ab structure, are
insufficient to confer even minimal binding to liposomes.
Biomolecular interactions are mediated by hydrophobic,
electrostatic, van der Waals and hydrogen bonds. The widely-
held presumption has been that 4E10 binds lipids, liposomes and
membranes through predominately hydrophobic interactions
mediated by HCDR3 and other combining site residues. In order
Figure 1. Analysis of 4E10H knock-in mice. (A) The percentages of IgM+IgD2 pre-B and IgM+IgD+ immature B cells within the B220+ cell
population in the bone marrow of B6 WT, B6-KL25H and B6-4E10H mice are shown. Marrow cells were isolated and stained for cell surface markers as
described in the methods section. FACS plots were previously gated B220+ and on live cell size based on forward and side scatter. Numbers represent
the percentages of B220+ bone marrow cells falling within each box gate. (B) The proliferation of B220+ splenocytes from B6 WT, B6-KL25H, and B6-
4E10H mice in response to overnight culture in the presence of B cell stimuli are shown. Cells were loaded with cell proliferation dye before overnight
incubation, and proliferation was assessed by FACS analysis after cell surface staining to identify B220+ B cells. Histograms were previously gated
B220+ and on live cell size based on forward and side scatter. Numbers represent the percentage of B220+ cells falling within the bar gate on each
plot, indicating dilution of the proliferation dye as a result of cell division.
doi:10.1371/journal.ppat.1003639.g001
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to determine the overall character of 4E10/liposome binding, SPR
analyses were conducted at a series of salt concentrations;
increasing the salt concentration drives hydrophobic interactions
but ablates electrostatic ones, which is the fundamental principle
behind ion exchange and hydrophobic interaction chromatogra-
phy. SPR analyses showed that 4E10 IgG interactions with both
Figure 2. SPR analyses of 4E10/liposome interactions. Corrected SPR responses are shown (response units: RU; duplicate runs) of Annexin V
(black), aCL polyclonal Ab (orange), 4E10 IgG (red), 2F5 IgG (blue), and b12 IgG (green) analytes binding to liposomes incorporating biotinylated lipids
captured on streptavidin-coated biosensor chips. All analyte concentrations were 300 nM. The Annexin V analyte buffer included 2.5 mM CaCl2.
Liposome compositions are indicated above each frame.
doi:10.1371/journal.ppat.1003639.g002
Figure 3. Design and characterization of HCDR3-grafted Ubq fusion proteins. (A) A ribbon representation of Ubq (1UBQ.pdb [106]) is
shown at bottom right, colored prismatically from N- (blue) to C-terminus (red); the targeted loop for HCDR3 engraftment is highlighted in gray with
red bounding residues. The structures of the three targeted HCDR3 segments in context of their parent Abs are shown above in a licorice-stick
representation, colored by atom type (oxygen: red; nitrogen: blue; carbons of buried residues: marine blue; and carbons of exposed residues: gray).
Residue exposure was determined with the program GetArea [107], with greater than 30% solvent accessibility considered ‘‘exposed’’, based on the
structural context in the corresponding crystal structures (2F5: 3IDG.pdb [108]; b12: 3RU8.pdb [104]; 4E10: 2FX7.pdb [9]). The three transferred
sequences (2F5: AHRRGPTTLFGVPIARGPVNAMDVW; b12: ARVGPYSWDDSPQYNYYMDVW; 4E10: AREGTTGWGWLGKPIGAFAHW; exposed
residues bolded), were characterized as ‘‘hydrophobic’’ with the Sigma-Aldrich PEPscreen Library Design Tool (W2F5 = 0.52; Wb12 = 0.51;
W4E10 = 0.56). Key residues and Ca-Ca distances (A˚) are indicated. The inset shows a schematic representation of the design process. Molecular
images were generated with MacPyMOL [109]. (B) SEC analyses of the solution properties of the purified recombinant HCDR3-grafted Ubq fusion
proteins are shown, confirming monodispersivity. (C) Corrected SPR responses (duplicate runs) of HCDR3-grafted Ubq fusion proteins to HIV SF162
gp140 protein amine-coupled to biosensor chips; analyte concentrations are indicated. While detectable, these responses are consistent with KD
values ..10 mM and are thus too weak to quantify reliably. (D) SPR responses (duplicate runs) of Annexin V and HCDR3-grafted Ubq fusion protein
analytes to liposomes incorporating biotinylated lipids captured on streptavidin-coated biosensor chips are shown, with liposome compositions
indicated above each frame. HCDR3-grafted Ubq fusion protein responses are colored as indicated, but none showed detectable binding on any
liposome composition.
doi:10.1371/journal.ppat.1003639.g003
Autoreactivity and Polyspecificity of bNAb 4E10
PLOS Pathogens | www.plospathogens.org 5 September 2013 | Volume 9 | Issue 9 | e1003639
CL-containing and virus-like liposomes were abolished by
increasing the salt concentration (Fig. 4A), demonstrating that
4E10 interacts with liposomes containing phospholipids with
negatively-charged headgroups (e. g. CL) predominately through
electrostatic interactions, not hydrophobic ones.
It had previously been suggested that 4E10 contains a
phosphate-binding subsite [50] and that a structurally-reasonable
phosphate binding site is present on the light chain side of the
combining site, bracketed by the side-chains of K32L and
K100eH [34]. In the latter study, a 4E10 [G(L50)E] IgG mutant
was constructed that places a glutamic acid side-chain directly
between the K32L and K100eH side-chains, designed to disrupt
phosphate binding. In order to identify features on 4E10 that
could mediate phospholipid interactions outside of hydrophobic
combining site residues, the [G(L50)E] mutant was tested for
liposome binding by SPR (Fig. 4B). However, 4E10 [G(L50)E]
IgG retained binding to liposomes containing CL and virus-like
liposomes, demonstrating that mutational ablation of the K32L/
K100eH site does not ablate phospholipid binding. Outside of the
K32L/K100eH site, inspection of available 4E10 structures,
Figure 4. Analysis of the effects of salt concentration, mutation and overall cassette charge on 4E10/liposome interactions.
Corrected SPR responses are shown for Annexin V or 4E10 IgG analytes (300 nM; duplicate runs) to liposomes incorporating biotinylated lipids
captured on streptavidin-coated biosensor chips; liposome compositions are indicated above each frame. (A) SPR responses of wild-type 4E10 IgG
analytes at different salt concentrations are plotted. (B) SPR responses of Annexin V (300 nM), wild-type 4E10 IgG (300 nM) or the 4E10 [G(L50)E]
mutant IgG (400 nM) are plotted. A higher concentration of 4E10 mutant IgG was used with the expectation that binding might be significantly
reduced. Since this did not occur, mutant IgG responses appear elevated due to the concentration differential. (C) The net charge at neutral pH of the
Fv cassettes of the anti-HIV Abs with structures currently available through the PDB [103] was calculated with the structure-based algorithm PDB2PQ
[51–54]. Two Abs, PG16 and NIH45-46, were excluded because their structures included modified amino acids that could not be accommodated by
PDB2PQ. Fvs are plotted with their names, with assigned PDB accession codes in parentheses. Ab labels are colored by the locale of their epitopes on
Env, as indicated; 4E10 is also bolded.
doi:10.1371/journal.ppat.1003639.g004
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which were all determined as complexes with HIV epitope-related
ligands, failed to reveal any obvious electropositive pocket, crevice
or groove that might be reasonably inferred to confer CL binding,
so no further targeted mutagenesis studies were performed.
Structure-based calculations of the net charges at neutral pH of
the Fv cassettes of all available anti-HIV antibody structures using
PDB2PQ [51–54], showed that 4E10 and 2F5 have exceptional
net positive charges (Fig. 4C). However, since this level of overall
electropositivity of 2F5 is insufficient to confer liposome binding, it
is also unlikely to account for 4E10 liposome binding.
The crystal structure of unbound 4E10 revealed a
completely restructured combining site
The species actually binding lipids in our studies was 4E10 free
of bound ligand, where all previous 4E10 structures were
determined as complexes with MPER epitope-related ligands.
While highly affinity-matured Abs tend to have rigidified
combining sites [55–67], we sought to crystallize free 4E10 to
identify potential structural flexibility that might explain these
discrepancies in the absence of alternative hypotheses. The 4E10
Fv in the unbound state was crystallized from Li2SO4
(dmin = 2.4 A˚), preliminary phases were determined by molecular
replacement, and the structure was rebuilt and refined with good
agreement statistics and geometry (Table 1). The asymmetric unit
contains four copies of 4E10, grouped as two pairs related by a
single NCS two-fold axis, arranged in a pinwheel-like pattern with
the HCDR3s forming the central spoke. VL domains of Fvs from
one member of each dyad-related pair are relatively poorly
ordered, likely due to sparse crystal contacts. Overall, the Fv
domains show a high degree of structural conservation to each
other, with the main differences arising from alternate HCDR1
and HCDR3 conformations between dyad-related pairs. The
HCDR3 conformation of one dyad-related pair is extended into a
solvent channel and unconstrained by crystal packing, with large
accompanying crystallographic B-factors, likely closely recapitu-
lating the free, solution-state structure (Fig. 5A). The HCDR3
conformation from the second dyad-related pair is alternatively
scrunched by extensive crystal packing and hydrophobic interac-
tions across the plane bisecting the dyad axis, resulting in low B-
factors stemming from these steric constraints. Comparison of the
presumed solution-state, unbound 4E10 conformer, using the
better-ordered dyad mate, with a reference epitope-peptide 4E10
Table 1. Crystallographic data collection and refinement statistics.
Synchrotron In-house
Data collection*
Space group C2221 C2221
Cell dimensions
a, b, c (A˚) 88.89, 161.6, 163.3 88.89, 161.6, 163.3
Resolution (A˚) 46.1-2.39 (2.44-2.39) 50.0-2.35 (2.43-2.35)
Rmerge 0.072 (0.382) 0.066 (0.438)
I/sI 28.45 (5.6) 22.97 (2.66)
Completeness (%) 100.0 (99.8) 99.9 (99.9)
Redundancy 8.3 (3.0) 4.1 (2.5)
Refinement











Bond lengths (A˚) 0.006 –
Bond angles (u) 0.899 –
Ramachandran plot statistics (MolProbity)
Residues in most favored regions (%) 97.6% –
Residues in disallowed regions (%) 0.0% –
MolProbity score 1.37 –
Est. coordinate error (max. likelihood ESUc; A˚) 0.161 –
Accession code 4LLV
*Values in parentheses are for the highest-resolution shell.
doi:10.1371/journal.ppat.1003639.t001
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Fab complex structure (2FX7.pdb [9]), showed that the largest
structural differences are also between HCDR1 and 3, with
movements of ,12 A˚ between the Ca positions of W100H in
HCDR3 and ,6 A˚ between the Ca positions of F29H in HCDR1
(Fig. 5A and B; pair-wise superpositions resulted in a root mean
square deviations (RMSD) on all common Cas of 0.76 A˚ for the
heavy chain, with HCDR1 and 3 deleted, and 0.32 A˚ for the light
chain). The movements of HCDR1 and 3 reposition the side-
chains of F29H and W100bH, which are both buried in the VH
domain in epitope complexes, to form hydrophobic interactions
partially covering the side-chains of L53H, L54H and I56H in
HCDR2. These three side-chains are exposed in the epitope
complex structures, making contacts with a hydrophobic face of
the MPER epitope. In the complex structures, HCDR3 forms the
back wall of the epitope binding pocket. In the unbound structure,
however, HCDR displacements remodel the 4E10 combining site,
completely occluding epitope binding but creating a shallow
concavity on the backside of HCDR3, a surface typically buried in
Ab structures. One of the ordered sulfates modeled into the
structure sits near the middle of this concavity, coordinated by the
guanidinium group of R94H and main-chain and side-chain
contacts from S28H.
4E10 did not stain HEp-2 cells by IF microscopy
4E10 had been reported to show diffuse cytoplasmic and
nuclear staining of HEp-2 cells [19,20], suggesting the presence of
a cross-reacting autoantigen. Higher resolution confocal micros-
copy of HEp-2 cells stained with 4E10 IgG was used to expand the
prior result by narrowing the subcellular localization and begin the
process of identifying the antigen/s. Fixed and permeabilized
HEp-2 cells were incubated with 4E10 or, as comparative controls,
b12 or an anti-protein disulfide isomerase (aPDI) IgG (Fig. 6). b12
has been reported to stain HEp-2 cells in a similar pattern, though
with stronger nucleolar staining in the nucleus, but this Ab has not
been reported to be autoreactive [16], and aPDI marks the
endoplasmic reticulum (ER). If 4E10 can bind CL with a
physiologically relevant affinity, 4E10 would be predicted to stain
cells with a mitochondrial pattern. The aPDI IgG stains HEp-2
cells in the expected ER pattern (Fig. 6A), but 4E10 and b12 bind
irreproducibly in replicate experiments and failed to show any
specific staining (Figs. 6B and C), negating this approach.
Analysis of 4E10 autoreactivity and polyspecificity using a
synthetic human peptidome
A phage-displayed library of 413,611 overlapping 36-mer
peptides spanning the complete human proteome [45] was used
to identify candidate autoantigens and assess the polyspecificity of
4E10; b12 was also analyzed for comparison (Figs. 7 and 8). In
this library, neighboring peptides in contiguous open reading
frames overlap by seven residues, the approximate size of a linear
Ab epitope. Both Abs were analyzed in duplicate, with results
plotted as replicate #1 versus replicate #2 2Log10 P-values [45].
Plotted in this way, highly discordant replicate pairs lie near the
axes and were discarded from further consideration; 241 36-mers
were also culled because of nonspecific binding. Based on
sequence searches, no sequence motifs associated with the core
epitope of 4E10 (NWFD/NIT) or alternate proposed HIV epitopes
[68] are present in the human proteome, so positive binding
results in these assays reflect truly polyspecific recognition of
distinct epitopes. b12 showed results consistent with a non-
autoreactive Ab of limited polyspecificity (Fig. 7A), with the
highest scoring peptide having a replicate average 2Log10 P-value
equal to 14.3 and with approximately two dozen peptides rising
above the main cluster (Figs. 7A and 8). Detailed inspection of the
15 top-scoring b12 36-mer peptides (Fig. 8) showed a consistent
pattern of highly positively-charged peptides (average predicted
net charge at neutral pH of +9) with blocks of low sequence
complexity in 12 of 15 peptides.
The 4E10 PhIP-Seq results were distinct from the b12 results
(Figs. 7B and 8). Using the highest scoring b12 peptide as a
benchmark under the assumption that b12 is not autoreactive, 17
36-mer peptides showed significantly higher scores (replicate
average 2Log10 P-values of 18.4 to 255). The chemical character
of these 17 4E10 peptides was distinct, as well: overall moderately
hydrophobic or hydrophobic (though none were very hydropho-
bic), with a range of predicted net charges at neutral pH from
25.7 to +1.9 and greater sequence complexity. None of the 17
high-scoring peptides had sequences related to HIV, as expected,
Figure 5. Structure of 4E10 free of bound antigen. (A) Superposition of the three HCDRs from bound and unbound b12 (3RU8.pdb [104],
1HZH.pdb [110] and 4E10 (2FX7.pdb [9], 4LLV.pdb) are shown in a B-factor putty representation (b12, blue: bound; cyan: unbound. 4E10, pink: bound,
yellow: unbound). (B) Superposition of residues from the 4E10 epitope binding site and HCDR1 and 3 from bound (semi-transparent molecular
surface in pink; 2FX7.pdb [9]) and unbound (mesh molecular surface in yellow; 4LLV.pdb) 4E10 Fv are shown; HCDR1 and 3 are shown in cartoon
representations with side-chains of key residues shown in licorice-stick representations and labeled. The molecule is oriented so that the VL domains
are to the left and the VH domains to the right. Molecular images were generated with MacPyMOL [109].
doi:10.1371/journal.ppat.1003639.g005
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but we were able to identify a conserved motif. Three of the five
top-scoring peptides, including the highest scoring peptide, are
derived from an ER-resident inositol trisphosphate receptor (IP3R;
NP_002214 [69,70]) [71]. MEME motif analysis [72] revealed a
highly conserved core motif (DEQGSKV/I
N/SDFF) within these
three peptides quite unrelated to the 4E10 MPER epitope (Fig. 7B
inset). While no homologous crystal structure is available, Phyre2
threading [73] predicts that this sequence forms part of an
extended helix in IP3R. The other two top-five scoring 36-mers
were from cytoplasmic dynein 1 intermediate chain 2 (NP_001369
[69,70]) and the complement receptor type 1 isoform S precursor
(NP_000642 [69,70]). None of the peptides from the top two
scoring proteins from the previously reported ProtoArray 5
analysis [20] (retinoid X receptor b and interleukin-1 family
member 6) or the proposed autoantigen, splicing factor 3B3
(SF3B3; ProtoArray 5 rank not reported), had average 2Log10 P-
values above 1.54 in the PhIP-Seq analysis (4E10 library
average = 0.27 (s= 0.82); b12 library average = 0.33 (s= 0.45)).
The close concordance in library scoring behavior also argues
against the presence of very broad, low-avidity binding by 4E10
relative to b12.
Validation of PhIP-Seq top-scoring peptides by SPR
The five top scoring peptides identified by PhIP-Seq (Fig. 8)
were further validated by testing for binding to 4E10 directly by
SPR. Peptides were expressed in a eukaryotic secretion-pathway
Figure 6. IF microscopy of HEp-2 cells. Fixed and permeabilized HEp-2 cells were stained with (A) aPDI IgG (an ER marker), (B) 4E10 IgG, or (C)
b12 IgG, appropriate fluorescently-labeled secondary Abs, and visualized microscopically. Image parameters were carefully matched across
experiments.
doi:10.1371/journal.ppat.1003639.g006
Figure 7. PhIP-Seq analyses of 4E10 and b12. PhIP-Seq results are plotted as 2Log10 P values, one replicate on the abscissa, the other on the
ordinate; note the discontinuity in axis scales. The top five scoring 4E10 peptides are highlighted with arrows; the three peptides derived from IP3R
isoform sequences are highlighted with green arrows, with the consensus core sequence shown as a MEME logo [72,111] in the inset. The orange
arrow corresponds to a peptide derived from cytoplasmic dynein 1 and the blue arrow to a peptide derived from complement receptor type 1. The
gray arc corresponds to the 2Log10 P values observed for the highest-scoring b12 peptide, so defines a threshold for potential autoreactive binding
events. Proximity to the diagonal indicates good replicate concordance; peptides with highly discordant replicate values, falling along the axes,
outside the bounding dashed red lines were discarded from the analysis.
doi:10.1371/journal.ppat.1003639.g007
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expression system as fusion constructs with the human protein
siderocalin (Scn; Fig. 9A) [74]; expression in bacterial systems
resulted in unacceptable levels of proteolytic degradation (data not
shown). The constructs incorporated various purification and
epitope-tags, including a C-terminal Strep-tag [75]. Western blots
(data not shown) and SPR analyses with an anti-Strep-tag Ab
confirmed the presence of full length peptides, with specific
activities assayed by SPR of 12% to 34% as coupled, which
allowed for normalizing results between SPR experiments
(Figs. 9B and C). All five peptides showed definitively positive
binding results (Fig. 9B), whereas no binding was seen to the
siderocalin construct minus peptide, confirming specific interac-
tions. Binding was reduced by 75% to 85%, but not ablated, in the
presence of 500 mM NaCl (Fig. 9C), indicating that the
interactions were not exclusively electrostatic in nature and
drawing a distinction with 4E10 recognition of liposomes. The
qualitative, normalized SPR responses monotonically decreased
from peptide #1 to #5 to fairly weak values, so no further peptide
fusions from hits farther down the PhIP-Seq list were evaluated.
IHC showed specific patterns of 4E10 staining
Previous IHC studies of the three isoforms of IP3R [76] show
that IP3R1 is markedly enriched in Purkinje neurons in the
cerebellum, IP3R2 is overwhelmingly found in glial cells and
IP3R3 is predominantly found in neurons, but not glia, and is
enriched in neuropil, especially in neuronal terminals in limbic
and basal forebrain regions. To further validate IP3R as the
candidate 4E10 autoantigen, serial sections from fixed, paraffin-
embedded mouse cerebellum were deparaffinized, rehydrated and
treated to retrieve antigens, followed by staining with either 4E10
or an IHC-validated anti-IP3R1 rabbit polyclonal Ab (LifeSpan
Biosciences LS-B2627) and appropriate secondary Abs. The
commercial anti-IP3R1 polyclonal was raised against a synthetic
peptide corresponding to C-terminal residues of human IP3R1,
cross-reacts with mouse and rat orthologs and strongly stains
Purkinje cells per the manufacturer’s specifications (LifeSpan
Biosciences). 4E10 strongly stained specific nodular substructures
in a subset of neurons, identified as Purkinje cells on the basis of
morphology, with minimal background staining of other cell types
or substructures in these sections (Fig. 10A and B). The anti-
IP3R1 polyclonal strongly stained a corresponding subset of
neurons, also identified as Purkinje cells, and stained a combina-
tion of similar nodular structures as well as exhibiting more diffuse
cytoplasmic and cellular process staining (Fig. 10C and D).
SF3B3, together with splicing factor 3a and a 12S RNA, forms the
U2 small nuclear ribonucleoprotein complex (U2 snRNP), which
Figure 8. Top scoring 4E10 and b12 PhIP-Seq 36-mer peptides. The top fifteen scoring 36-mer peptides from the b12 IgG PhIP-Seq analysis
(above) and the seventeen top scoring 36-mer peptides from the 4E10 IgG analysis exceeding the threshold set by the highest-scoring b12 peptide
(below) are shown, compiled by their relative rank order, replicate-averaged PhIP-Seq score, sequence, identity of the parent protein, hydrophobicity
(W) and predicted charge at neutral pH. Hydrophobicities were determined with the Sigma-Aldrich PEPscreen Library Design Tool (green: hydrophilic;
orange: moderately hydrophobic; red: hydrophobic; no peptides were predicted to be ‘‘very hydrophobic’’); overall charge was determined with the
Innovagen Peptide Property Calculator (red: negative; green: neutral; blue: positive). Segments of low sequence complexity (defined by the program
SEG [112]) are highlighted in red; the core motif in the IP3R isoform peptides (labeled in bold), identified by MEME [72], is underlined. Asterisks
indicate peptide sequences selected for expression as fusion constructs for subsequent validation.
doi:10.1371/journal.ppat.1003639.g008
Figure 9. SPR analyses of Scn-peptide fusions. (A) The generalized siderocalin fusion construct used for PhIP-Seq peptide expression is shown.
(B) Corrected and normalized SPR responses for 4E10 IgG binding to the top five peptides immobilized on a CM5 biosensor chip are plotted. (C)
Corrected and normalized SPR responses of 4E10 IgG (300 nM; duplicate runs) binding to peptides (colored as in (B)) at 500 mM NaCl are plotted;
inset shows magnified view. Normalized SPR responses are plotted in arbitrary units.
doi:10.1371/journal.ppat.1003639.g009
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is localized to the nucleus [77]. The staining patterns of both 4E10
and the anti-IP3R1 polyclonal were inconsistent with recognition
of antigens widely-expressed across cell types, like CL or SF3B3, or
exclusively nuclear antigens, like SF3B3.
Discussion
When applying ‘‘reverse vaccinology’’ [78] to the design of an
HIV vaccine, it is important to determine whether or not the
targeted bNAbs, e.g. 4E10, are autoreactive, and, if so, whether
autoantigen recognition is separable from antigen recognition and
neutralization. Despite usage of a breadth of murine light chains,
4E10H knock-in mice exhibited a profound blockade during B cell
development consistent with the induction of central tolerance
mechanisms, in which immature B cells expressing an autoreactive
BCR are deleted (Fig. 1). In addition, the small residual
population of B cells exported to the periphery, while able to
respond to a variety of mitogenic signals, was unable to proliferate
in response to IgM cross-linking. This phenotype substantiates the
hypothesis that 4E10 is autoreactive. The questions then arise as to
what autoantigen/s are mediating deletion and anergy and
whether the mechanisms of 4E10 recognition of HIV and
autoantigen epitopes are interdependent or separable, permitting
the design of immunogens that generate Abs functionally
equivalent to 4E10 with focused specificities that evade central
and peripheral tolerance mechanisms.
Refined SPR analyses of Ab/liposome interactions (Fig. 2)
confirmed that 4E10 binds to liposomes with compositions that
include negatively-charged lipids (CL, PS), but not net neutrally-
charged liposomes that contain only PC and cholesterol; by
contrast, 2F5, b12 and ACLA show no binding to liposomes of any
composition tested. The failure of ACLA to bind to CL-containing
liposomes was likely accounted for by the absence, in these
experiments, of required protein binding partners, like b2GPI, and
draws a clear distinction between 4E10 binding behavior and
autoimmune ACLA responses. The bivalent avidity of 4E10 for
negatively-charged liposomes was weak compared to the univalent
affinity of Annexin V binding. Crystal structures of 4E10/epitope
peptide complexes [8–10,34] limited how 4E10 might interact
with lipids, liposomes or membranes (Fig. 11A). The MPER
epitope peptide, structured as a short a-helix with a turn at the N-
terminus, fits into a deep pocket in the Ab combining site, the back
side of which consists of HCDR3. Two small hydrophobic patches
are found centered on the side-chains of L53H, L54H and I56H,
packing against a complementary hydrophobic face on the
structured epitope peptide in complex structures, and W100H,
which extends outwards from the tip of HCDR3. However,
neither patch is particularly large or exceptional for Ab combining
sites, as can be seen in comparison with 2F5 (Fig. 11B). Since 2F5
did not display liposome binding (Fig. 2), hydrophobic patches of
this size order are not likely sufficient to account for 4E10 lipid
binding.
The exposed side-chain of W100H on an extended HCDR3
structure, a feature which is shared with b12 (Fig. 11C), is
positioned to potentially interact with membranes, but the side-
chain of W100bH is partially buried behind the heavy chain N-
Figure 10. IHC of serial mouse cerebellar sections. (A) Immunohistochemical staining with 4E10 IgG in mouse cerebellum sections reveals
perinuclear, nodular immunoreactivity in Purkinje neurons; inset shows a magnified view. (B) Human IgG Isotype control staining of mouse
cerebellum is shown. (C) Staining for IP3R1 with an anti-IP3R1 IgG shows a perinuclear, nodular and diffuse cytoplasmic staining pattern in Purkinje
neurons, mirroring that seen in (A); inset shows a magnified view. (D) Rabbit IgG isotype control staining of mouse cerebellum is shown.
doi:10.1371/journal.ppat.1003639.g010
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terminus and the backbone of HCDR3 (Fig. 11A), rendering it
inaccessible for docking to an encountered lipid bilayer. However,
a sole exposed tryptophan side-chain on an extended HCDR3 is
not sufficient on its own to confer liposome binding, otherwise b12
would also have displayed binding (Fig. 2), as it shares this feature
with 4E10. We note that Annexin V also has a sole exposed
tryptophan side-chain (Fig. 11D) which also does not support
liposome binding in the absence of CL, PS or calcium (Fig. 2).
Tryptophan side-chains can partition into lipidic phases, but
typically influence the precise positioning of integral membrane
proteins rather than confer membrane binding [79–81], consistent
with our results. The sequence of the 4E10 HCDR3 segment is
quite hydrophobic overall, but is mostly buried in the core of the
protein (Fig. 3A). HCDR3 peptides from 2F5, b12 or 4E10, even
when fully exposed as grafted Ubq-fusion constructs, did not
measurably bind to liposomes of any composition tested, showing
that hydrophobic, tryptophan-rich HCDR3 sequences are also
insufficient to confer lipid binding out of context of an intact Ab.
Many examples of crystal structures showing specific CL
recognition are available (e. g. cytochrome bc1 complexes, like
1P84.pdb [82]). In these structures, the acyl chains of CL are
typically found wedged in hydrophobic grooves or packed against
extensive hydrophobic faces, while the phosphoglycerol-phosphate
head group of CL makes polar contacts with positively-charged
residues on the protein, with CL bound in a deeply invaginated,
highly shape-complementary site. However, SPR analyses of 4E10
binding to liposomes in response to increasing salt concentrations
showed that the binding was dominated by electrostatic interac-
tions (Fig. 4A), drawing a clear distinction with examples of
specific CL recognition in protein crystal structures, which are
dominated by apolar and van der Waals interactions within a
subset of specific, polar bonds. The previously available 4E10
crystal structures, determined as complexes with epitope ligands,
did reveal a potential phosphate binding site, between the side-
chains of K32L and K100eH, albeit in the absence of a crevice or
groove complementary to a full CL headgroup. However,
mutational ablation of this site did not reduce binding to
negatively-charged liposomes (Fig. 4B). No other candidate
phosphate or CL binding sites were apparent from inspection of
the complex crystal structures. Annexin V binds PS via a pair of
metal coordination sites interacting with negatively-charged
phosphate and carboxylate groups (Fig. 11D), hence membrane
binding is calcium-dependent, but 4E10 liposome binding is not
(Fig. 2), suggesting a different recognition mechanism; 4E10 is
also not known to bind metal ions and does not possess
recognizable metal binding sites.
The substantial reordering of the 4E10 combining site in the
unbound state, however, uncovers an electropositive pocket large
enough to accommodate various phospholipid headgroups,
including the diphosphoglycerol headgroup of CL (Fig. 11E).
An ordered sulfate ion occupies one end of this pocket in the
crystal structure, designating a possible phosphate-binding subsite
(SO4
22 and PO4
22 ions are chemically and structurally similar
and can interact interchangeably within a protein binding site
[83,84]). CL coordinates were extracted from 1P84.pdb and
modeled into this site by rigidly docking one of the CL phosphate
moieties onto the position of the ordered sulfate ion and manually
adjusting for optimal fit, which was easily achieved (Fig. 11F).
This pocket readily accommodates the CL headgroup without
clashes, with the second phosphate moiety making reasonable
interactions with the side-chain of H102H, approximately 7 A˚
away from the sulfate site, and the main-chain nitrogens of Q1H
and V2H. Docking CL in this manner orients the lipid tails
outwards from the Ab, sterically accommodating docking to a
negatively-charged liposome surface. While fitting CL well, the
pocket does not display close shape complementarity, permitting
other phospholipid headgroups to bind, consistent with the
observed recognition degeneracy and weak absolute affinities.
Because the residues involved in inferred CL contacts in this site all
make important contributions to the overall structure of 4E10 in
the complex structures, cleanly interpretable mutagenesis studies
could not be performed.
We conclude that 4E10 is not specific for CL; rather, 4E10
weakly and non-specifically interacts with phospholipid head-
groups or liposomes carrying a net negative charge primarily
through electrostatic interactions associated with an electropositive
pocket on the unbound conformer of 4E10. As displayed by the
absence of binding to control liposomes, 4E10 does not show a
general proclivity to indiscriminately bind liposomes, consistent
with this conclusion. Such weak, non-specific, electrostatic binding
of phospholipids is unlikely to be relevant to B cell tolerance
induction nor is likely a requirement for neutralization, consistent
with prior studies that showed reducing liposome affinity did not
ablate neutralization [34], but may contribute generally to
targeting of viral surfaces. However, since CL recognition is likely
mediated by a pocket on the 4E10 combining site present only in
the unbound form of 4E10, CL binding would directly compete
with MPER epitope binding. In others words, 4E10 must release
weakly bound CL before or concurrent with adopting the CDR
conformation required to bind its MPER epitope and, therefore,
cannot use membrane associations as a guide to direct epitope
binding. The requirement to undergo a large conformational shift
is consistent with the relatively slow association kinetics and weak
overall affinity (KD = 135 nM) observed when binding to Env
proteins [34]; sampling an ensemble of CDR conformers may also
contribute to the unusual biphasic association kinetics observed by
SPR when binding liposomes.
Figure 11. Structures of 4E10, b12, 2F5, the CL-binding yeast cytochrome bc1 complex and Annexin V. (A) The structure of the Fv
domain of 4E10 (from 2FX7.pdb [9]) is shown in a semi-transparent molecular surface representation colored by electrostatic potential (blue: positive;
red: negative). Side-chains of key residues are shown in licorice-stick representations and labeled. In this orientation, the VL domain is in the upper left
and the VH domain is in the lower right. The backbone of the epitope peptide co-crystallized in this structure is shown in a cartoon representation,
with side-chains shown in licorice-stick representations colored by atom-type (carbon: gray; oxygen: red; nitrogen: blue). (B) The molecular surfaces of
the Fv domains of 4E10 (top) and 2F5 (bottom) are shown, oriented with VL domains at left and the VH domains at right. The surface is colored to
show hydrophobic patches, defined by the program HotPatch [113]; patches are colored in descending order of total area (red, orange, yellow …).
Key residues and hydrophobic patch areas are indicated. (C) The structure of the Fv domain of b12 (from 3RU8.pdb [104]) is shown as in (A). (D)
Annexin V (1A8A.pdb [114]) is shown as a semi-transparent molecular surface colored by underlying atom type, highlighting the exposed tryptophan
side-chain (shown in licorice-stick representation). Calcium ions, shown as green spheres, coordinate the phosphate moiety from PS (shown in a
licorice-stick representation, colored by atom-type as in (A) plus phosphorus in orange). (E) The structure of the unbound form of 4E10 (4LLV.pdb) is
shown as a semi-transparent molecular surface representation colored as in (A). Side-chains of key residues are shown in licorice-stick representations
and labeled. The view of the molecule has been rotated roughly 45u from the orientation of 4E10 shown in (A). The coordinated SO4 ion is shown in a
licorice-stick representation colored by atom type as in (A) plus sulfur in yellow. (F) CL is shown docked onto the unbound structure of 4E10 oriented
and colored as in (E). Molecular images were generated with MacPyMOL [109].
doi:10.1371/journal.ppat.1003639.g011
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Discarding CL from consideration, we utilized an unbiased
proteomic approach to identify novel autoantigen candidates and
to more fully characterize the polyreactivity of 4E10. A synthetic
representation of the complete human proteome, composed of
overlapping 36 amino acid peptides, was displayed on T7 phage
and coupled with parallel DNA sequencing (PhIP-Seq) [45]. The
PhIP-Seq method offers many improvements to prior methods,
including the breadth of coverage and its quantitative nature [45].
36-mers are long enough to retain substantial secondary and
residual tertiary structure from the intact, folded, parent protein,
potentially allowing identification of conformational epitopes.
However, 36-mers are unlikely to represent stably folded species,
and these peptides likely sample large conformer ensembles,
including many non-native (non-self) states, increasing their utility
for assaying polyspecificity. Since the peptides span a wide range
of chemical properties (hydrophobic vs. hydrophilic, aromatic vs.
charged vs. zwitterionic), the total conformer space also likely
encompasses many peptide mimetics of non-protein species. A
caveat with this approach is the difficulty in identifying discontin-
uous epitopes spanning more than one peptide, though linear
segments of discontinuous epitopes may retain detectable binding.
However, epitopes inaccessible in folded proteins, but which are
exposed by proteolytic cleavage or other antigen processing events
during B cell selection, can potentially be identified.
241 peptides were culled from the analysis because of uniform
binding across a larger array of distinct Abs, but additional
peptides retained in the analysis showed strong binding to more
than one Ab in broader analyses not reported here, so binding
results do not necessarily reflect just the specificity or polyspeci-
ficity of the Ab tested, but may also reflect the polyspecificity of a
peptide. b12, an Ab that is presumably not autoreactive or
unusually polyreactive, was analyzed to provide a baseline for
PhIP-Seq results. The dozen top-scoring b12 peptides rising above
the bulk response (Fig. 8) showed a common pattern of high
positive charge and low sequence complexity, consistent with
describing these peptides as poorly-ordered globs of positivity. The
structure of b12 (Fig. 11C) is consistent with this observed, weak
polyspecificity. Four aspartic acids adjacent to W100H, clustered
on one face of the extended HCDR3 hairpin, form a large
negatively-charged patch ideal for binding such peptides, at least
weakly, as observed, and reveals a previously unrecognized aspect
of b12 binding. The absence of extreme enrichments is consistent
with the presumption that b12 is not self-reactive.
4E10, on the other hand, showed a strikingly different result
(Figs. 7B and 8), with highly-significant enrichment for 17
peptides well beyond the 10215 P-value threshold set by b12, the
top five with P-values ranging from 10258 to 102255, consistent
with functional autoreactivity and limited, focused polyspecificity
quite distinct from b12. There is no evidence that 4E10 displays an
exceptional, low-avidity polyreactivity from these results, especially
in comparison with b12. The 17 top-scoring 4E10 peptides,
constituting novel candidate autoantigens, were moderately
hydrophobic to hydrophobic in nature overall, with a range of
net charge, consistent with ordered parts of folded proteins. The
top-scoring 4E10 peptide is derived from IP3R2, with additional
hits from two related IP3R types (IP3R1 and IP3R3) within the top-
scoring five peptides (Fig. 8), providing evidence that one, two or
all three IP3R types constitute candidate 4E10 autoantigens. None
of the peptides from the top two scoring proteins from the
ProtoArray 5 analysis [20] ranked in the top 232,000 peptides; the
highest scoring peptide from the alternate proposed 4E10
autoantigen SF3B3 had a replicate-averaged 2Log10 P-value of
1.54, ranking it at 143,927. We also note that of the top 17 4E10
PhIP-Seq peptides, only four, numbers 11 (WD repeat-containing
protein 6), 12 (ras-GEF domain-containing family member 1A), 15
(UBX domain-containing protein 6 isoform 1) and 16 (complex I
intermediate-associated protein 30, mitochondrial precursor), are
from proteins represented on the ProtoArray 5, potentially
accounting for the discordance in results between these two
approaches. Scoring in PhIP-Seq also reflects internally-controlled
peptide binding and not binding relative to a reference antibody,
as in [20], which is necessarily affected by the binding profile of the
reference antibody.
Three types of IP3R were identified as top-scoring PhIP-Seq hits
and validated by SPR. In neuronal cell lines, IP3R1 and IP3R3 are
expressed predominantly in the ER and perinuclear regions, while
IP3R2 is expressed primarily in the nucleus [85]. IP3R3 shows an
evenly diffuse cytoplasmic staining pattern, but the IP3R1
cytoplasmic pattern is more punctate, with strongly-staining
nodular structures apparent [85]. However, failure to demonstrate
binding of 4E10 to HEp-2 cells (which are not known to highly
express IP3Rs) prevented comparative immunofluorescence anal-
yses. We therefore sought to determine if the PhIP-Seq results
identifying IP3R1, IP3R2 and IP3R3 as top candidate autoantigens
were consistent with 4E10 recognition in a tissue-specific context
by IHC. 4E10 staining of mouse cerebellar sections showed
perinuclear staining of nodular structures specifically in Purkinje
neurons, mirroring the staining of an anti-IP3R1 control
polyclonal antibody. The 4E10 staining pattern observed was
most consistent in terms of cell specificity with IP3R1 IHC patterns
reported in previous studies [76], strongly arguing that IP3R1 is
the lead candidate for a 4E10 autoantigen. The 4E10 staining
pattern observed was also inconsistent with recognition of SF3B3.
SF3B3, together with splicing factor 3a and a 12S RNA, forms the
U2 small nuclear ribonucleoprotein complex (U2 snRNP) which is
exclusively localized to the nucleus and widely-expressed across
cell types [77].
Confirmation that 4E10 is autoreactive helps to identify the
reasons vaccination strategies have failed, as tolerance mecha-
nisms would limit the generation of anti-HIV Abs equivalent to
4E10. Our findings have important implications for future
strategies to induce MPER-specific bNAbs. While lipid cross-
reactivity mediated by HCDR3 had been suggested to play a
role both in inducing B cell tolerance and in increasing
neutralization potency through interactions with viral mem-
branes, mutual functionalities precluding an engineered solu-
tion, our results alternately suggest that viral membrane binding
is so weak and nonspecific, and competes with HIV epitope
binding, that it is unlikely to be involved in the induction of
tolerance mechanisms or to play a key role in neutralization.
Weak but detectable binding of HCDR3 ubiquitin fusions to
gp140s suggests that HCDR3 may make interactions to Env,
rather than membrane, outside of the core 4E10 epitope.
Neutralizing anti-influenza Abs (e. g. Abs CR6261, F10, FI6 and
C179) often interact with a hydrophobic groove in the
membrane proximal stalk region of hemagglutinin (HA)
delineated by helix A and HA2 through hydrophobic HCDR
residues [86–90]. The hydrophobic HCDR3 of 2F5, which
recognizes an MPER motif neighboring the 4E10 epitope, has
been argued to make similar contacts in the MPER region of
Env as part of its neutralization mechanism [91]. We speculate
that 4E10 may make analogous interactions to those seen in
anti-HA Abs and 2F5, where 4E10 HCDR flexibility and
hydrophobicity enable interactions with the presumed helical
bundle of HIV gp41. However, the structure of the unbound
form of 4E10 suggests that the long HCDR3 of 4E10 may also
serve a role to shield hydrophobic patches in the combining site
important for MPER recognition, prior to Env binding.
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The fundamental concern in eliciting 4E10-like bNAbs was that
viral epitope recognition would not be separable from autoantigen
recognition. However, we showed that the viral epitope is not
mimicking a self-antigen, because 4E10-selected sequences in the
PhIP-Seq array analysis completely diverged from the 4E10 core
epitope. The alternate core motif epitope from the likeliest
candidate autoantigens, the three types of IP3R, was completely
distinct from the 4E10 core epitope. Therefore, because the
molecular mechanisms employed by 4E10 to recognize such
divergent sequences are likely also distinct, even if they involve
partially overlapping sites, it may be possible to ablate recognition
of self-reactive epitopes while preserving interactions with
neutralizing MPER epitopes. Future studies should concentrate
on determining the complex crystal structure of 4E10 bound to the
IP3R epitope in order to guide efforts towards engineering an
immunogen that will elicit a non-autoreactive 4E10-like bNAb.
However, if functional ontogeny of 4E10-equivalent responses
requires engineering the ability to sample multiple, distinct
conformers, in order to shield hydrophobic surfaces necessary
for functional MPER recognition or to enable other molecular
mechanisms necessary for recognition and/or neutralization, and
if conventional Ab maturation typically proceeds by structural
stabilization of the lone conformer optimal for epitope binding (e.
g. [67]), it may not be possible to recapitulate 4E10-equivalent
activities by any conventional immunization strategy.
Materials and Methods
Generation and analysis of 4E10H knock-in mice
4E10H targeted transgenic (knock-in) mice were generated by
targeted insertion of a DNA construct encoding a mouse
immunoglobulin heavy chain (IgH) promoter upstream of the
rearranged Ab 4E10 IgH VDJ antigen-binding domain plus an
mRNA splice donor sequence. The transgene was targeted to the
mouse IgH genomic locus upstream of the immunoglobulin
constant domains utilizing homologous recombination in C57BL/
6 (B6) strain mouse embryonic stem (ES) cells. Transgene targeting
was confirmed in ES cell clones by Southern blot (data not shown).
4E10H knock-in B6 ES cells were microinjected into FVB strain
blastocysts, which were implanted into pseudo-pregnant female
mice. Chimeric knock-in pups were identified by coat color and
PCR genotyping, and crossed with B6 mice to generate pure B6
strain 4E10H knock-in mice. Germline transmission of the
targeted 4E10H allele to progeny was confirmed by PCR
genotyping (data not shown). Knock-in mice were inter-bred to
establish homozygosity of the knock-in allele as assessed by PCR
genotyping (data not shown). B6 background TgH(KL25) knock-in
mice (referred to here as KL25H mice), expressing the mouse
LCMV-neutralizing antibody KL25 rearranged IgH VDJ antigen-
binding domain from the mouse IgH locus [46], were generously
provided by Daniel Pinschewer (University of Geneva).
In order to analyze the composition of the bone marrow in
transgenic animals, age-matched female wild type B6, KL25H
knock-in, and 4E10H knock-in mice 6 to 8 weeks of age were
euthanized and leg bones were isolated by dissection. Bone
marrow was flushed from the leg bones with cold B cell media
(RPMI/10% FBS/Penicillin/Streptomycin/2-mercaptoethanol)
using a syringe and 18 g needle. Red blood cells were lysed with
ACK lysing buffer (Gibco) and live cells were purified by density
gradient centrifugation using Histopaque 1119 (Sigma-Aldrich).
56106 live cells from each mouse were stained with anti-mouse
B220-Alexa647, IgM-PE, IgD-V450, and CD4-FITC (BD Biosci-
ences), and analyzed on a FACS Canto II flow cytometer (BD
Biosciences; Fig. 1A).
In order to analyze the ability of knock-in B cells to proliferate,
splenocytes were purified from B6, KL25H, and 4E10H mice by
density gradient centrifugation using Histopaque 1083 (Sigma-
Aldrich). Purified cells were loaded with cell proliferation dye
eFluor670 (eBioscience) according to the manufacturer’s instruc-
tions. 16106 cells per well were incubated overnight in round-
bottom 96-well plates with or without B cell stimuli (LPS, CpG
DNA, an activatory anti-CD40 antibody, or anti-IgM F(ab9)2) in B
cell media, in a 37uC CO2 cell culture incubator. The following
day, cells were stained for cell surface markers (B220 and Thy1.2)
and B cell proliferation was assessed by flow cytometry (Fig. 1B).
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Liposome preparation
Lipids were purchased from Avanti Polar Lipids: bovine heart




ovine wool cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethano-
lamine-N-biotinyl (biotinylated PE). Control liposomes (4:1 w/w
PC:cholesterol), CL liposomes (1:7:2 w/w CL:PC:cholesterol), and
viral mimic liposomes (3.2:5.4:5.1:4.8:10.2 w/w cholester-
ol:PC:SM:PE:PS) [22], each containing 0.5% w/w biotinylated
PE, were prepared by mixing each lipid component in chloroform,
evaporating the solvent, and then resuspending at a final
concentration of 1 mg/mL in phosphate buffered saline (PBS). In
control and CL liposomes, PC was included as egg L-a-
phosphatidylcholine, while in viral mimic liposomes, PC was
included as 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine. Lip-
id solutions were incubated at 65uC for 5 min and then subjected to
five freeze/thaw cycles alternating between a dry ice ethanol bath
for 3 min and a 65uC water bath for 3 min with intermittent
vortexing. Solutions were then passed through an extruder (Avanti)
with a 0.1 mm polycarbonate membrane (Avanti) 21 times.
Protein expression and purification
HCDR3-grafted Ubq fusion constructs (Fig. 3) with C-terminal
His6-purification tags were engineered, cytoplasmically expressed
in E. coli BL21(DE3) RIL cells (Invitrogen), and purified employing
the methodology described in [92]. 4E10 [G(L50)E] IgG was
produced as described in [34]. Seven of the top ten scoring 4E10
binding peptides identified in the PhIP-Seq analyses were cloned
as fusion constructs with the human protein Scn [74] (Fig. 9A)
using direct synthesis of human codon-optimized DNA (IDT) and
Gibson cloning [93,94] (GeneArt Seamless Cloning kit, Invitro-
gen) and expressed in HEK293 Freestyle cells (Invitrogen) using
the Daedalus lentiviral transduction system [74]. Scn-peptide
fusion constructs were purified by SEC from concentrated culture
supernatants and validated by PAGE and Western analyses as
described in [74] (data not shown).
SPR interaction analyses
All SPR experiments were performed at 25uC on a Biacore
T100 instrument with the T200 sensitivity enhancement (GE
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Healthcare). Liposome experiments (Figs. 2, 3D and 4) were run
in 10 mM HEPES, pH 7.4, 150 mM NaCl and 0.5 mg/mL BSA
(HBS-N-BSA) on SA sensor chips (GE Healthcare). Liposome
preparations containing 0.5% biotinylated lipids were injected at
50 to 100 mg/mL, 5 mL/min, until approximately 1000 SPR
response units (RUs) were captured, then allowed to equilibrate for
four hours at 10 mL/min. Flow cell 1 was left blank as a reference
surface. Single concentrations of 4E10 IgG (Polymun Scientific),
2F5 IgG (Polymun Scientific), b12 IgG (the kind gift of Pamela
Bjorkman, Caltech), human ACLA polyclonal serum (LifeSpan
BioSciences), and Annexin V (BD Biosciences) 62.5 mM CaCl2,
all at 300 nM (Figs. 2 and 4), or 4E10[G(L50)E] IgG [34] at
400 nM (Fig. 4B) and the three HCDR3-grafted Ubq-fusions at
1 mM (Fig. 3D), were injected in duplicate analyses at 50 mL/min
for three minutes and allowed to dissociate for five minutes. In the
salt series experiment (Fig. 4A), 4E10 IgG was diluted to 300 nM
in HBS-N-BSA with added NaCl to 575, 320, or 150 mM total
NaCl and analyzed in matched running buffers. HIV gp140
SF162 trimers [34] at 30 mg/mL in 10 mM sodium acetate
(pH = 5.0) were immobilized at a density of 3250 RUs on a CM5
sensor chip (GE Healthcare) using standard amine coupling
chemistry (Fig. 3C). An activated/deactivated flow cell was used
as a reference surface. HCDR3-grafted Ubq-fusions were injected
in duplicate experiments in 10 mM HEPES, pH 7.4, 150 mM
NaCl, 3 mM EDTA, 0.05% (v/v) surfactant P20 (HBS-EP+) at
1 mM and 5 or 10 mM (depending on maximum responses) at
50 mL/min for three minutes and allowed to dissociate for six
minutes (Fig. 3C). Approximately 3000 RUs of each Scn-peptide
fusion construct or a Strep-tagged Scn control [74] were
immobilized on CM5 chips (GE Healthcare) using standard
amine coupling chemistry and HBS-EP+ as running buffer
(Fig. 9); optimal immobilization conditions were determined for
each fusion by pH scouting. DTT was included in the
immobilization buffer for fusions 1 and 3 to prevent oxidation of
cysteines in the 36-mer peptide sequences. Duplicate 4E10 IgG
samples at 300 nM were injected at 50 mL/min for three minutes
and allowed to dissociate for 15 minutes in HBS-EP+ or HBS-EP+
at 500 mM NaCl. In order to determine the specific activity of the
fusion-coupled surfaces, each Scn-peptide fusion surface was
saturated with StrepMAB-Immo IgG (IBA BioTAGnology) by
making three five minute injections of 100 nM IgG at 30 mL/min.
Final SPR responses of 4E10 IgG binding to Scn-peptide fusions
(Fig. 9) were normalized in Scrubber 2.0b (Biologic) software by
comparing the observed specific activities (fusion #1: 13%; fusion
#2: 14%; fusion #3: 29%; fusion #4: 12%; fusion #5: 34%; Scn
controls: 51% or 40%). Specific activities are reduced from 100%
by either steric occlusion through coupling or proteolytic
degradation of the Scn-peptide fusions. All SPR data were
double-referenced [49] using BiaEval version 2.0.3 (GE Health-
care) and plotted with Prism 5.0d for Mac OSX software.
Crystallography
Crystals of ligand-free 4E10 Fv [34], expressed without
purification tags using the Daedalus system [74], were grown at
25uC by the hanging-drop vapor-diffusion method with a well
solution of 0.8 M Li2SO4 buffered with 0.1 M NaOAc (pH = 4.6).
Crystals grew within one week and were cryopreserved in a
mother liquor of well solution plus 15% v/v glycerol. Diffraction
data were collected with both CuKa radiation on an in-house R-
AXIS IV++ image plate detector with HR optics (Rigaku) at
2170uC and at the Advanced Light Source beamline 5.0.2 (ALS;
Lawrence Berkeley National Laboratory, Berkeley, CA) and
reduced using HKL-2000 [95]. Initial phase information was
determined by molecular replacement with Phaser [96], as
implemented in the CCP4i program suite [97], a previous bound
4E10 structure (3H3P.pdb [34]), with CDRs deleted, as a search
model. Phases were improved by subsequent rounds of model
building and refinement using COOT [98] and REFMAC [99]
with the ALS data. Eight TLS groups, one for each heavy and
light chain, were used during refinement [100,101]. Structure
validation was carried out with the MolProbity server [102], and
the RCSB ADIT validation server. An anomalous difference
Fourier synthesis, using in-house native data reduced without
merging Bijvoet pairs, was calculated to verify SO4 placement and
the initial correctness of the molecular replacement solution.
Crystallographic statistics are reported in Table 1 and the final
coordinates have been deposited in the PDB [103], accession code
4LLV.
PhIP-Seq analysis
For each of the two Abs analyzed, 3 mg of magnetic beads
(Invitrogen Dynabeads M-270 Epoxy) were resuspended in 60 mL
0.1 M NaPO4, pH 7.4. Beads were rocked at ambient for 24 hrs
with 60 mg of either 4E10 or b12 IgG in 1 M (NH4)2SO4 and then
washed with 10 mM glycine in PBS to cap unreacted epoxy
groups. Activity of 4E10 and b12 beads was confirmed by epitope-
scaffold [92,104] binding prior to PhIP-Seq analyses. PhIP-Seq
analyses were performed as described in [45,105]. Briefly, 4E10
and b12 beads were incubated with the T7-Pep library. DNA from
immunoprecipitated phage was recovered and sequenced. Two
replicate experiments were performed for both 4E10 and b12 and
the enrichment significance for each clone was calculated as
2Log10 P-values.
IHC
Four micron sections of formalin-fixed and paraffin-embedded
tissues were cut and baked for 1 hr at 60uC, deparaffinized with
xylene and rehydrated in a series of graded ethanol solutions
(100%, 95%, and 80%) followed by distilled water. Antigen
retrieval in pH 6.0 Citrate Buffer (Dako Target Retrieval Solution
S1699) was then performed for 5 min in a pressure cooker. All of
the following incubations were performed at room temperature on
a Dako Autostainer Plus. Wash buffer (0.05M Tris, 0.3M NaCl,
and 0.1% Tween-20, pH 7.2–7.6) was used between all subse-
quent steps except between the protein block step and application
of the primary Ab. A 3% v/v hydrogen peroxide block step was
done for 8 min. IP3R1 staining: a protein block step consisting of
0.05M Tris, 0.15M NaCl, 0.25% Casein, 0.1% Tween 20, pH 7.6
(TCT Buffer) was performed for 10 minutes. Tissues were then
stained with polyclonal rabbit anti-human IP3R1 IgG (LifeSpan
Biosciences) at a dilution of 1:200 (2.5 mg/mL) or rabbit IgG
matched to the protein concentration of the primary Ab for
60 minutes. Mach 2 Rabbit HRP-polymer (Biocare Medical
RHRP520L) was applied for 30 minutes. 4E10 staining: avidin
block (Biocare Medical AB972M-A) was applied for 10 minutes,
followed by biotin block (Biocare Medical AB972M-B) for
10 minutes. Next, a protein block step (TCT Buffer plus 15%
goat serum) was performed for 10 minutes. Tissues were then
stained with 4E10 IgG (Polymun AB004) at a dilution of 1:100
(10 mg/mL) or normal human serum matched to the protein
concentration of the primary Ab for 60 minutes. The Fab of a
biotinylated goat anti-human secondary Ab (Jackson Laboratory
109-067-993) was applied for 30 minutes followed by incubation
with streptavidin-HRP (Jackson Laboratory 016-030-084) at a
dilution of 1:2000 for 30 minutes. Finally, a DAB+ substrate-
chromogen incubation was done (Dako K3468) for two applica-
tions of 4 min each. The slides were counterstained with
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Automation Hematoxylin (Dako S3301) for 2 minutes and then
coverslipped.
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